Revolutionary treatments
for addiction
Revolutionary treatments
for addiction
About Awakn
Awakn Life Sciences is a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder
OBJECTIVE:
To provide effective therapeutics to addiction sufferers in desperate need
STRATEGY:
To commercialize our R&D pipeline across multiple channels
Drugs and therapies used in combination
Addiction is one of the world’s biggest unmet medical needs. Substance and behavioural addictions affect over 1.3¹ billion people worldwide. Yet all current treatments have high failure rates.
Awakn is developing a better solution to treat addiction: psychedelic therapeutics – drugs and therapies used in combination. We are a biotech company researching, developing and commercializing these therapeutics.
Through clinical trials, our team has shown that this approach has the potential to be more effective than any addiction treatment currently available. We now aspire to become the market leader in effective addiction treatment, meeting a vast global need that is failed by current approaches.
Addiction: The other pandemic
Between 15-20% of adults suffer from substance addictions¹, and many others from behavioural addictions.
Yet available treatments are poor. Just 16% of Alcohol Use Disorder sufferers seek treatment, and up to 75%² of those people relapse within 12 months. Behavioural addictions are so poorly served there is no good data available on either treatment or success rates.
Despite these high failure rates, $17bn³ per year (and rising) is spent by on private addiction treatment. The individuals footing this bill have a right to expect more.
Our unique evidence-based approach
Awakn is developing a revolutionary new approach for treating substance and behavioural addictions.
Based on new research, Awakn’s drugs uniquely target the brain circuits that drive addiction, through multiple receptors rather than the single drug receptors targeted by existing treatments. These circuits control the behavioural drivers of addiction. By focusing on circuit mechanisms rather than isolated receptors, our treatments have the potential to be effective in the treatment of both substance and behavioural addictions.
This brain circuit-disruption allows the individual to engage with Awakn’s psychotherapeutic process in unique ways that enable clients to escape repetitive addictive behaviours and thoughts; and make long lasting positive changes.
Awakn’s team has successfully conducted the world’s only clinical trials of ketamine and MDMA in a therapeutic setting as treatments for alcohol use disorder. We are now conducting trials for other addictions, including gambling, Binge Eating Disorder, Internet Gaming Disorder and Compulsive Sexual Bahavior and building a pipeline of patentable psychedelic therapeutics that will create even more effective medicines in future.
Together, this gives us a world-beating proposition for tackling addiction.
Working with the world’s leading research institutions
Investment Highlights
Significant market opportunity and proven science that can provide effective therapy to patients in desperate need.
Significant Addressable Market
- 285 million people globally are affected by AUD
- Global AUD treatment market is valued at US$25bn per annum
- Existing AUD treatments lack efficacy, with 75% relapse rates
Deep Pipeline With Proven Efficacy
- Lead program progressing to Phase III – 3.5 times more effective than the current standard of care
- Appropriate IP strategies in place
- Deep pipeline developed with relatively low capital investment
Commercialization
- Currently commercializing R&D assets in 4 territories and across 2 revenue streams in advance of marketing authorization
- Potential future value creation opportunities through out-licensing or sale of R&D Assets
Highly Experienced Team
- Global leading addiction experts - ‘punching above weight’ – across board & management teams
- Track record of successful research, development and commercialization
- Supportive ‘blue chip’ investor base
References:
1. Source: Prevalence of the Addictions: A Problem of the Majority or the Minority? Steve Sussman, Nadra Lisha, and Mark Griffiths
2. Source: “Treatment rates for alcohol use disorders: a systematic review and meta-analysis” by Tesfa Mekonen.
3. Source: Reports and Data (reportsanddata.com) - Drug Addiction Treatment Market.
Sign Up for Newsletter
MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom
UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom
© 2021 Awakn Life Sciences Corp | Privacy Policy | Appropriate Use Policy
